IL1B and juvenile idiopathic arthritis: In 2015, Cassyanne L Aguiar et al. reported that a 2-year-old systemic juvenile idiopathic arthritis (JIA) patient tolerated canakinumab safely after allergic reaction to anti-IL-1 therapy (anakinra) [15].